The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

Some megatrends in health care are occurring that deserve our attention. We already know that as much as one-third of the U.S ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...